SCHEMBL6533053

SCHEMBL6533053

COCCNc1ccc2c(=O)[nH]c3ncccc3c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.54
PARP1 P09874 1/20 0.54
POLB P06746 1/20 0.48
PKM P14618 1/20 0.48
UTS2R Q9UKP6 2/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
SLC40A1 Q9NP59 2/20 0.46
CDC7 O00311 2/20 0.45
ROCK2 O75116 1/20 0.45
PIM1 P11309 1/20 0.45
PRKACA P17612 1/20 0.45
CDK2 P24941 1/20 0.45
GSK3B P49841 1/20 0.45
CDK7 P50613 1/20 0.45
CDK9 P50750 1/20 0.45
HIPK2 Q9H2X6 1/20 0.45
IRAK4 Q9NWZ3 1/20 0.45
GRM4 Q14833 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6521479 0.82 CDK2 (0.50) AURKAPARP1PKMCYP1A2CYP2C9
SCHEMBL6525846 0.80 AURKA (0.47) AURKAPARP1CDC7MEN1KMT2A
SCHEMBL6525635 0.80 AURKA (0.56) AURKAPARP1CYP1A2PIM1ALDH1A1
SCHEMBL6527186 0.79 MAPT (0.51) AURKAPARP1POLBPKMCDC7
SCHEMBL6517375 0.79 AURKA (0.51) AURKAPARP1MAPT
SCHEMBL6523008 0.79 PARP1 (0.51) AURKAPARP1SLC40A1
SCHEMBL6518864 0.78 AURKA (0.51) AURKAPARP1CYP1A2CYP2C19MEN1
SCHEMBL6524125 0.78 ELANE (0.48) AURKAPARP1CDC7MEN1KMT2A
SCHEMBL3454371 0.78 AURKA (0.60) AURKAPARP1CDC7ROCK2PIM1
SCHEMBL6517544 0.78 FGFR1 (0.51) AURKAPARP1ROCK2CDK9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 AURKA 538/4885PARP1 1693/4885POLB 2583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.